Abstract
Salivary gland tumors are rare, clinically diverse neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. While numerous small phase II studies have evaluated the activity of cytotoxic agents, either alone or in combination, the response rates are generally modest with objective response rates ranging from 15%–50%. Duration of response is cited in the range of 6–9 months. Given this, further evaluation of novel therapies is mandatory in these diseases. With the emergence of molecular targeted therapy, these tumors become optimal candidates for trials of investigational drugs and established drugs for new indications. Of note, given the often indolent nature of disease, only patients with progressive disease should be enrolled and treated on these clinical trials. Study designs must incorporate stringent inclusion criteria to enable accurate reporting of disease response and stabilization. With dedication and co-operation, patients with these rare neoplasms can be accrued to clinical trials and the establishment of new treatment guidelines will be forthcoming.
Similar content being viewed by others
References
Speight PM and Barrett AW (2002) Salivary gland tumours. Oral Dis/Oral Dis 8:229–240
Jones AV, Craig GT, Speight PM et al (2007) The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol/Oral Oncol
Gooden E, Witterick IJ, Hacker D et al (2002) Parotid gland tumours in 255 consecutive patients: Mount Sinai Hospital’s quality assurance review. J Otolaryngol/J Otolaryngol 31:351–354
Mendenhall WM, Riggs CEJ, Cassisi NJ (2005) Cancer: Principles and Practice of Oncology. Journal/Treatment of head and neck cancers 662–732
Arshad AR (1998) Parotid swellings: report of 110 consecutive cases. Med J Malaysia/Med J Malaysia 53:417–422
Daley T and Darling M (2003) Nonsquamous cell malignant tumours of the oral cavity: an overview. J Can Dent Assoc/J Can Dent Assoc 69:577–582
Loyola AM, de Araujo VC, de Sousa SO et al (1995) Minor salivary gland tumours. A retrospective study of 164 cases in a Brazilian population. Eur J Cancer B Oral Oncol/Eur J Cancer B Oral Oncol 31B:197–201
Theriault C and Fitzpatrick PJ (1986) Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol/Am J Clin Oncol 9:510–516
Licitra L, Grandi C, Prott FJ, et al. (2003) Major and minor salivary glands tumours. Crit Rev Oncol Hematol/Crit Rev Oncol Hematol 45:215–225
Witt RL (2004) Major salivary gland cancer. Surg Oncol Clin N Am/Surg Oncol Clin N Am 13:113–127
Atula T, Grenman R, Klemi P et al (1998) Human papillomavirus, Epstein-Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. Oral Oncol/Oral Oncol 34:391–395
Karja V, Syrjanen K and Syrjanen S (1997) No Epstein Barr and cytomegalovirus DNA found in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec/ORL J Otorhinolaryngol Relat Spec 59:97–99
Sun EC, Curtis R, Melbye M et al (1999) Salivary gland cancer in the United States. Cancer Epidemiol Biomarkers Prev/Cancer Epidemiol Biomarkers Prev 8:1095–1100
Brandwein MS, Ferlito A, Bradley PJ et al (2002) Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol/Acta Otolaryngol 122:758–764
Seifert G and Donath K (1996) Hybrid tumours of salivary glands. Definition and classification of five rare cases. Eur J Cancer B Oral Oncol/Eur J Cancer B Oral Oncol 32B:251–259
Guzzo M, Andreola S, Sirizzotti G et al (2002) Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol/Ann Surg Oncol 9:688–695
Goode RK, Auclair PL and Ellis GL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer/Cancer 82:1217–1224
Brandwein MS, Ivanov K, Wallace DI et al (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol/Am J Surg Pathol 25:835–845
Spiro RH, Huvos AG and Strong EW (1982) Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients. Am J Surg/Am J Surg 144:423–431
Davies L and Welch HG (2006) Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg/Otolaryngol Head Neck Surg 135:451–457
Batsakis JG, Regezi JA, Luna MA, et al. (1989) Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol Otol/J Laryngol Otol 103:939–944
Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck-a 20 years experience. Int J Oral Maxillofac Surg/Int J Oral Maxillofac Surg 33:25–31
Waldron CA, el-Mofty SK and Gnepp DR (1988) Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral Surg Oral Med Oral Pathol/Oral Surg Oral Med Oral Pathol 66:323–333
Buchner A, Merrell PW and Carpenter WM (2007) Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med/J Oral Pathol Med 36:207–214
Wahlberg P, Anderson H, Biorklund A et al (2002) Carcinoma of the parotid and submandibular glands-a study of survival in 2465 patients. Oral Oncol/Oral Oncol 38:706–713
Yih WY, Kratochvil FJ and Stewart JC (2005) Intraoral minor salivary gland neoplasms: review of 213 cases. J Oral Maxillofac Surg/J Oral Maxillofac Surg 63:805–810
Conley J and Arena S (1963) Parotid Gland as a Focus of Metastasis. Arch Surg/Arch Surg 87:757–764
Nichols RD, Pinnock LA and Szymanowski RT (1980) Metastases to parotid nodes. Laryngoscope/Laryngoscope 90:1324–1328
Greene F (2002) AJCC Cancer Staging Manual
Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer/Cancer 85:2255–2264
Gunderson LL and Tepper JE (2007) Clinical Radiation Oncology
Armstrong JG, Harrison LB, Spiro RH et al (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg/Arch Otolaryngol Head Neck Surg 116:290–293
Frankenthaler RA, Luna MA, Lee SS, et al (1991) Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg/Arch Otolaryngol Head Neck Surg 117:1251–1256
North CA, Lee DJ, Piantadosi S, et al (1990) Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys/Int J Radiat Oncol Biol Phys 18:1319–1326
Spiro IJ, Wang CC and Montgomery WW (1993) Carcinoma of the parotid gland. Analysis of treatment results and patterns of failure after combined surgery and radiation therapy. Cancer/Cancer 71:2699–2705
Brackrock S, Krull A, Roser K et al (2005) Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. Anticancer Res/Anticancer Res 25:1321–1326
Day TA, Deveikis J, Gillespie MB et al (2004) Salivary gland neoplasms. Curr Treat Options Oncol/Curr Treat Options Oncol 5:11–26
Perez CA, Brady LW and Halperin EC (2004) Principles and Practice of Radiation Oncology
Ben-David MA, Diamante M, Radawski JD et al (2007) Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys/Int J Radiat Oncol Biol Phys 68:396–402
Laurie SA and Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol/J Clin Oncol 24:2673–2678
Licitra L, Marchini S, Spinazze S et al (1991) Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer/Cancer 68:1874–1877
Airoldi M, Brando V, Giordano C et al (1994) Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL J Otorhinolaryngol Relat Spec/ORL J Otorhinolaryngol Relat Spec 56:105–111
Dimery IW, Legha SS, Shirinian M et al (1990) Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol/J Clin Oncol 8:1056–1062
Hill ME, Constenla DO, A’Hern RP et al (1997) Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol/Oral Oncol 33:275–278
Dreyfuss AI, Clark JR, Fallon BG et al (1987) Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer/Cancer 60:2869–2872
Alberts DS, Manning MR, Coulthard SW et al (1981) Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer/Cancer 47:645–648
Venook AP, Tseng A Jr., Meyers FJ et al (1987) Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol/J Clin Oncol 5:951–955
Airoldi M, Pedani F, Brando V, et al. (1989) Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori/Tumori 75:252–256
de Haan LD, De Mulder PH, Vermorken JB et al (1992) Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck/Head Neck 14:273–277
Triozzi PL, Brantley A, Fisher S et al (1987) 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer/Cancer 59:887–890
Airoldi M, Pedani F, Succo G et al (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer/Cancer 91:541–547
Gedlicka C, Schull B, Formanek M et al (2002) Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs/Anticancer Drugs 13:491–495
Airoldi M, Fornari G, Pedani F, et al. (2000) Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res/Anticancer Res 20:3781–3783
Gilbert J, Li Y, Pinto HA et al (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck/Head Neck 28:197–204
Harari PM and Huang SM (2000) Modulation of molecular targets to enhance radiation. Clin Cancer Res/Clin Cancer Res 6:323–325
Agulnik M, Cohen EE, Cohen RB et al (2006) A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings/J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 24:5566
Chen CH, Li BY, Wan JT et al (2001) Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc Natl Sci Counc Repub China B/Proc Natl Sci Counc Repub China B 25:90–96
Etges A, Pinto DS, Jr., Kowalski LP et al (2003) Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol/J Clin Pathol 56:914–918
Fan CY, Melhem MF, Hosal AS et al (2001) Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg/Arch Otolaryngol Head Neck Surg 127:1075–1079
Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A et al (1997) Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg/J Craniomaxillofac Surg 25:328–334
Vered M, Braunstein E and Buchner A (2002) Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck/Head Neck 24:632–636
Yamada K, Iwai K, Okada Y et al (1989) Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol/Virchows Arch A Pathol Anat Histopathol 415:523–531
Rubin Grandis J, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst/J Natl Cancer Inst 90:824–832
Barnes L, Rao U, Contis L et al (1994) Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol/Oral Surg Oral Med Oral Pathol 78:74–80
Cho KJ, Kim JY, Lee SS et al (1997) Mucoepidermoid carcinoma of the salivary gland—a clinico-pathologic and immunohistochemical study for c-erbB-2 oncoprotein. J Korean Med Sci/J Korean Med Sci 12:499–504
Cho KJ, Lee SS and Lee YS (1999) Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck/Head Neck 21:414–419
Dori S, Vered M, David R et al (2002) HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med/J Oral Pathol Med 31:463–467
Felix A, El-Naggar AK, Press MF et al (1996) Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol/Hum Pathol 27:561–566
Glisson B, Colevas AD, Haddad R et al (2004) HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res/Clin Cancer Res 10:944–946
Karja V, Syrjanen S, Kataja V et al(1994) c-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec/ORL J Otorhinolaryngol Relat Spec 56:206–212
Kernohan NM, Blessing K, King G et al (1991) Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol/J Pathol 163:77–80
Press MF, Pike MC, Hung G et al(1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res/Cancer Res 54:5675–5682
Shintani S, Funayama T, Yoshihama Y et al (1995) Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res/Anticancer Res 15:2623–2626
Skalova A, Starek, Kucerova Vet al (2001) Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neuoncoprotein overexpression. Pathol Res Pract/Pathol Res Pract 197:621–626
Skalova A, Starek I, Vanecek T et al (2003) Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology/Histopathology 42:348–356
Sugano S, Mukai K, Tsuda H et al (1992) Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope/Laryngoscope 102:923–927
Giannoni C, el-Naggar AK, Ordonez NG et al (1995) c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg/Otolaryngol Head Neck Surg 112:391–398
Nagler RM, Kerner H, Ben-Eliezer S et al (2003) Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. Oncology/Oncology 64:389–398
Stenman G, Sandros J, Nordkvist A et al (1991) Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer/Genes Chromosomes Cancer 3:128–135
Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol/Oral Oncol 39:724–727
Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol/J Clin Oncol 25:3978–3984
Penner CR, Folpe AL and Budnick SD (2002) C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol/Mod Pathol 15:687–691
Holst VA, Marshall CE, Moskaluk CA et al(1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol/Mod Pathol 12:956–960
Jeng YM, Lin CY and Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett/Cancer Lett 154:107–111
Hotte SJ, Winquist EW, Lamont Eet al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol/J Clin Oncol 23:585–590
Lim JJ, Kang S, Lee MR et al (2003) Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med/J Oral Pathol Med 32:552–561
Doi R, Kuratate I, Okamoto E et al (1999) Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas. J Oral Pathol Med/J Oral Pathol Med 28:259–263
Ellis GL and Auclair PL (Armed Forces Institute of Pathology, 1996) Tumors of the salivary glands. Atlas of Tumor Pathology, third series, Fascicle 11
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agulnik, M., McGann, C.F., Mittal, B.B. et al. Management of salivary gland malignancies: current and developing therapies. Oncol Rev 2, 86–94 (2008). https://doi.org/10.1007/s12156-008-0062-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12156-008-0062-4